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Abstract Despite the clinical and prognostic improvement
obtained with the current medical treatment, heart failure
(HF) continues to have high morbidity and mortality and its
prevalence is increasing in most regions of the world. Thus,
there is a need for novel adjunctive therapies that act inde-
pendently of current neurohormonally and haemodynami-
cally oriented drugs. Nutritional approaches are particularly
attractive because they could work additively with estab-
lished therapies without negative hemodynamic effects.
There is growing evidence that omega-3 polyunsaturated
fatty acids (n-3 PUFAs) supplementation positively impacts
established pathophysiological mechanisms in HF and thus
has a potential role for preventing and treating HF. The
results of the GISSI-HF trial have indicated that, in patients
with chronic HF on evidence-based therapy, long term
treatment with PUFAs reduced mortality and hospitaliza-
tions for cardiovascular reasons, irrespective of etiology and
left ventricular (LV) ejection fraction (EF). The purpose of
this review is to summarize the evidence emerged from
studies conducted so far on the effect of n-3 PUFAs in HF.
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Introduction
Heart failure is a widespread disease in the world and is
estimated to affect 5 million people in the United States alone
[1, 2]. Annual costs related to the treatment of HF in the
United States are estimated at $38 billion, accounting for
5.4% of the healthcare budget [3]. The gold standard for
treatment of HF has been based on medical guidelines pub-
lished by groups such as the American Heart Association
(AHA), American College of Cardiology (ACC), Heart
Failure Society of America (HFSA), and the European
Society of Cardiology (ESC) [4–6]. The recommended
pharmacological therapy includes the use of angiotensin
converting enzyme (ACE)-inhibitors, angiotensin receptor
blockers (ARBs), diuretics, beta-blockers, and aldosterone
antagonists. These pharmacological regimens have shown
beneficial outcomes in Quality Of Life, morbidity, and/or
mortality in HF patients [4]. Despite improvements in mor-
tality, HF hospitalizations continue to rise, as an aging
population lives longer secondary to increased overall life
expectancy and improvements in HF therapy [7]. As more
patients survive after acute myocardial infarction, thanks to
improved revascularization strategies and better prevention
of sudden cardiac death, they are often left with decreased
LV function and HF [8]. Development of HF continues to be
one of the strongest predictors of short-term readmission and
mortality, with both rates remaining high despite current
therapies [9]. Thus, while new medication options have
improved morbidity, there remains substantial work to be
done to reverse the disabling signs and symptoms of HF [10].
Over the past 30 years much epidemiological evidence
and many experimental and clinical studies have supported
a protective role of n-3 PUFAs in the prevention and
treatment of cardiovascular diseases, particularly in coro-
nary artery disease (CAD) and sudden cardiac death
(SCD). Based on the results obtained from the GISSI-
Prevenzione [11], the European Society of Cardiology and
the American Heart Association (AHA) have approved n-3
PUFAs supplementation (combination of Eicosapentaenoic
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Acid, EPA, and Docosahexaenoic Acid, DHA) at a dose of
1 g/day in patients with documented CAD, also suggesting
a higher dietary intake of omega-3 (at least 2 meals of fish
per week) for primary prevention of cardiovascular disease
in patients without documented CAD [12, 13]. PUFAs have
also recently garnered increased attention in HF prevention
and treatment. The purpose of this review is to summarize
the evidence emerged from studies conducted so far on the
effect of n-3 PUFAs in HF patients.
Omega-3 Polyunsaturated fatty acids: metabolism
and biological effects in heart failure
Biochemical and biological aspects
Omega-3 are defined as essential fatty acids since they
cannot be synthesized in our body, but a dietary intake,
especially through oily fish (herring, mackerel, salmon,
albacore tuna, sardines) or fish oil supplementation is needed
[14]. There are two classes of PUFAs: omega 3 (a- linolenic
acid, LNA) and omega 6 (linoleic acid, LA). Both PUFAs
are metabolized to long-chain fatty acids of 20 and 22 carbon
atoms: LA is metabolized to arachidonic acid (AA) and
LNA to EPA and DHA. They are important components of
membrane’s phospholipids and at this level they compete for
the same enzymatic system, since their metabolism is
completely separated and their interconversion is not pos-
sible [15]. When humans ingest fish or fish oil, EPA and
DHA partially replace omega 6 fatty acids, especially ara-
chidonic acid (AA), in all cells’ membrane, favorably
modifying omega6/omega3 ratio. Thus a greater ingestion of
EPA and DHA from fish or fish oil leads to: (1) a decreased
production of thromboxane A2 leading to vasodilatation and
reduction in platelet aggregation; (2) a decrease in leuko-
triene B4 synthesis, a powerful inducer of leukocyte che-
motaxis and inflammation; (3) a decrease in cytokines levels
(IL1, IL6, TNFa) with a reduced inflammatory response to
endothelial and tissue damage; (4) a modulation of ionic
membrane channels conduction; (5) a modulation of intra-
cellular signal transduction and gene expression through the
regulation of several transcriptional nuclear factors. [16, 17].
A large number of structural and functional abnormali-
ties may play an important role in the pathogenesis of HF:
atherothrombosis, arrhythmias, abnormalities in energy
metabolism, altered expression or function of contractile
proteins, abnormalities of excitation–contraction coupling,
cytoskeletal abnormalities, alterations in the beta-adrener-
gic-receptor signal transduction, ventricular hypertrophy
and remodeling, and neurohormonal-cytokine changes
[18]. The clinical benefit of n-3 PUFAs may be mediated
by their effects on many of these processes and mecha-
nisms (Table 1).
Metabolic effects: energy metabolism
and mitochondrial function
Experimental data provided strong evidence that n-3 PU-
FAs are endogenous ligands for peroxisome proliferators
activated receptors alpha and gamma (PPARa and PPARc)
[19, 20]. LV hypertrophy and enlargement induced by
pressure overload are associated with a decrease in the
activity of mitochondrial enzymes involved in the fatty
acid oxidation and energy transduction. Omega-3 PUFAs
supplementation could preserve cardiac mitochondrial
function by stimulating expression of proteins involved in
cardiac lipid metabolism and mitochondrial function [21,
22]. Pepe and McLennan [23] showed that isolated per-
fused hearts from rats fed with fish oil, in comparison with
control group, had reduced myocardial oxygen consump-
tion without a decrease in LV power generation, at low or
high workload, resulting in greater LV mechanic effi-
ciency. The mechanism for this effect is not clear, but
could be due to improved mitochondrial coupling and/or a
decrease in ATP hydrolysis by processes not directly
related to force generation.
Anti-inflammatory effects
Persistent inflammation, involving increased levels of
inflammatory cytokines and vasoconstrictor eicosanoids,
seems to play a pathogenic role in chronic HF by influ-
encing heart contractility, inducing hypertrophy and
Table 1 Beneficial effects of n-3 PUFAs in heart failure
Hemodynamics Improve endothelium-dependent and
independent vasodilatation
; ET-1
: NO
Antinflammatory ; NF-jB activation
Compete with AA for COX and 5- lipoxigenase
enzymatic sites
Cardiac
energetics
: ATP generation
; O2 consumption
; sarcoplasmatic reticulum Ca2?
Remodeling and
fibrosis
: PPARc ? : adiponectin
Vascular ; Platelet aggregation via ;TXA2
; VCAM-1, ELAM 1, ICAM 1
; Monocyte endothelial adherence via ; PAF
Antiarrhythmic : EPA: AA ratio in plasma membrane
: Ca2? –Mg2? ATPase activity
Inhibit fast voltage-dependent Na? channels
Inhibit L-type Ca2?-channel
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promoting apoptosis, contributing to myocardial remodel-
ing and to deterioration of renal function [24, 25].
The anti-inflammatory effect of n-3 PUFAs may be
linked to their ability to modulate the nuclear transcription
factor (NF-jB) which is activated in HF [26–28]. The
PPARs activation may lead to a suppression of NF-jB and
NF-jB-regulated pro-inflammatory cytokines. In a small
pilot study, conducted on 14 patients with HF (NYHA class
III–IV) randomized to 8 g/day of EPA and DHA, there was
a reduction in cytokine (TNF-a and IL-1) levels and an
improvement in the percentage of body fat, suggesting that
omega-3 can decrease inflammation and prevent cachexia
in advanced HF patients [29]. In a recent study the treat-
ment with n-3 PUFAs in elderly patient with HF signifi-
cantly decreased plasma levels of TNFa, IL-6, intracellular
adhesion molecule 1 and NT-proBNP [30]. In another
study, Eschen et al. [31] showed that n-3 PUFAs in 138
congestive HF patients did not significantly affect the
plasma levels of circulating soluble cellular adhesion
molecules and high sensitivity C-reactive protein, but they
reduced P-selectin levels confirming their effect on platelet
and endothelial activation.
In adipocytes, n-3 PUFAs from fish oil increase
expression, secretion and plasma levels of the anti-
inflammatory hormone adiponectin. Recent studies showed
that adiponectin limits LV hypertrophy, remodeling, and
contractile dysfunction in response to pressure overload
and exerts anti-inflammatory effects [32]. The mechanisms
for adiponectin-induced suppression of LV hypertrophy
and dysfunction have been linked to activation of AMP-
activated protein kinase (AMPK) [33, 34], but could also
be due to inhibition of the serine–threonine kinase (Akt)
[35]. However, despite the activation of AMPK by adipo-
nectin, there is no direct clinical evidence of a strong
relationship between adiponectin and HF. In the Fra-
mingham Offspring Study, adiponectin was not associated
with the development of new HF, but resistin, another
adipokine, resulted in a link with HF [36]. Duda et al. [37,
38] in their studies in rats showed that EPA?DHA sup-
plementation increased adiponectin and lowered TNF-alfa
serum levels in a dose-dependent manner. Anyway
omega-3 supplementation did not affect the activation of
AMPK or Akt, suggesting that the protective effect of
adiponectin could be mediated by other mechanisms, such
as the modulation of NF-jB activity.
Hemodynamic effects
Several studies have shown additional beneficial effects of
n-3 PUFAs on HF development and progression by
affecting hemodynamic and LV function [39]. These
studies reported an improvement in endothelial function
[40, 41] and a reduction in systemic vascular resistances by
increasing the nitric oxide production [42, 43], a reduction
in vasoconstrictive response to norepinephrine and angio-
tensin II, an improvement in arterial compliance and vas-
cular response to vasodilators [44, 45]. These effects may
justify the reduction of systolic (-2.1 mmHg, p \ 0.001)
and diastolic (-1.6 mmHg, p \ 0.001) blood pressure
(BP), reported in a recent meta-analysis of 36 randomized
clinical trials, with an average dose of 3.7 g/day of
EPA?DHA; this modest BP reduction resulted greater in
older ([45 years) and hypertensive patients (BP C 140/
90 mmHg) [46].
Favorable effects of omega-3 administration on heart
rate (HR) were also reported. A meta-analysis of 30 ran-
domized studies showed that chronic administration of
EPA?DHA (about 3.5 g/day, for a period longer than
12 weeks) can lead to a reduction in HR of about 2.5–3
beats/min in subjects with a baseline HR of 69 beats/min
[47].
In addition, some experimental studies have shown that
chronic administration of n-3 PUFAs can lead to an
improvement in both systolic and diastolic myocardial
function [48, 49] and can prevent the development of LV
hypertrophy and systolic dysfunction induced by a pressure
overload [38]. In a idiopathic dilated cardiomyopathy
animal model, the long-term treatment with n-3 PUFAs
induced a significant increase in isometric and isotonic
contractile force of papillary muscles, an increase in the
actin-myosin bridges [50], and a significant improvement
in the peak rate of rise and fall of muscle tension, indi-
cating a more efficient contraction and muscle relaxation,
respectively [51]. These effects are probably related to
the prevention of overloading of intracellular Ca2? and
reduction of this ion in the sarcoplasmic reticulum [52].
Antiarrhythmic effects
Tachyarrhythmias are one of the most important causes of
death in patients with HF. Electrophysiological substrates
of arrhythmias in HF are numerous and include LV
remodeling, increased wall stress, heterogeneity of depo-
larization current, remodeling of ion channels and sim-
pathovagal unbalance. Myocardial ischemia, electrolyte
abnormalities, drugs, or fluctuations in the autonomic
system may be the triggers [53]. Different mechanisms by
which n-3 PUFAs may exert their antiarrhythmic effects
have been reported, including anti-inflammatory and anti-
thrombotic effects, modulation of ion channels (Ca2? and
Na?) and simpathovagal balance [54–57].
The antiarrhythmic properties of n-3 PUFAs have been
demonstrated in experimental models [58, 59] and in
clinical trials in patients with CAD [11, 60] while the trials
conducted in patients with an implantable cardioverter
defibrillator (ICD) have yielded controversial results [61–
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64]. These conflicting data may be due to several meth-
odological differences regarding study population and
follow-up, but the use of different formulations and doses
of n-3 PUFAs may represent an important explanation. In
fact, although the SCD reduction in the GISSI-Prevenzione
was obtained with low dose of omega-3, it was demon-
strated that the relative risk of SCD is associated with
baseline blood levels of n-3 PUFAs [65] and their antiar-
rhythmic effects in ischemic patients with ICD are related
to the increased n-3 PUFAs’ concentration in cell mem-
branes during treatment [64].
In addition, little is yet known about the impact of dif-
ferent etiology of HF (ischemic and non-ischemic) on the
results of treatment with omega-3. In our study [66], we
evaluated the effectiveness of n-3 PUFAs in reducing the
arrhythmic risk in patients with idiopathic dilated cardio-
myopathy and with frequent or repetitive ventricular
tachyarrhythmia episodes (NSVT), despite optimized drug
therapy. At the end of the 6-month follow-up, we observed
in n-3 PUFAs group, in comparison with placebo group, a
significant reduction in the number and duration of epi-
sodes of NSVT (p = 0.0002) and a decrease of average
HR of VT at Holter monitoring (p = 0.0003), with an
improvement of heart rate variability (HRV) (p \ 0.001)
and a reduction of catecholamine and cytokine serum
levels (p \ 0.001). The n-6/n-3 PUFA ratio was signifi-
cantly reduced in the treatment group from 1.12 to 3.48. As
noted in other series [67, 68], the reduction in plasma levels
of catecholamines and cytokines, in addition to increased
HRV, were related to the increase in concentrations of EPA
and DHA, confirming the impact of n-3 PUFAs on
important pathogenic mechanisms of arrhythmias in non-
ischemic HF patients.
n-3PUFAs in heart failure: epidemiological
and interventional studies
EPA and DHA modulate favorably several factors related
to the pathophysiology of HF, including the levels of fatty
acids, energy metabolism of myocytes, mitochondrial
function, inflammatory response and endothelial function.
All these effects could contribute to prevent or delay the
development and progression of HF. However, while there
are more data in the literature to support a role of
EPA?DHA supplementation in primary and secondary
prevention of CAD [69, 70], until now there are only few
evidences to support their benefit in HF patients.
Mozaffarian et al. [71] investigated the association
between fish consumption and incidence of HF in the
Cardiovascular Health Study, a population-based cohort
study including 4,738 adults, aged [65 years. Their
hypothesis was that consumption of tuna and other broiled
or baked fish, but not fried fish, would be associated with a
lower incidence of HF. During 12-years follow-up, 955
participants developed HF. In multivariate-adjusted anal-
yses, tuna/other fish consumption was inversely associated
with incident HF.
Another study [72] analyzed the association between
fatty acid levels and HF incidence in 15,792 subjects aged
between 45 and 64 years. During 14.3 years of follow-up
197 cases of HF were identified. After adjustment for age
and other confounders, while the levels of saturated fatty
acids (palmitic acid) were directly correlated with the
incidence of HF in both sexes, levels of n-3 PUFAs showed
an inverse correlation in women. Finally, Levitan et al. [73]
have studied the possible correlation between HF incidence
and fish consumption in a cohort of subjects aged
45–79 years in Sweden. In contrast to the study of Moz-
affarian [71], the association between fish consumption and
the incidence of HF showed U-shaped distribution in
multivariate analysis of consumption quintiles: patients in
the first quintile (0.15 g/day of fish) had a lower percentage
of HF although not statistically significant (-12%) com-
pared to no fish consumption, as well as patients in the
third quintiles (0.36 g/day) had a reduced risk of HF by
33% compared to those in the fifth quintiles (0.76 g/day).
The authors justify this result by assuming that subjects
with a greater intake of fish could be more vulnerable to the
adverse effects of fish’s contaminants (mercury, dioxides)
or could have more cardiovascular risk factors (hypercho-
lesterolemia and hypertension).
The first clinical study on the administration of n-3
PUFAs in patients with HF was the GISSI-HF Investigators
et al. [74]. A total of 6,975 HF patients (NYHA class II–IV)
were randomized to 1 g/day of n-3 PUFAs (850–882 mg/day
EPA ?DHA) as ethyl ester or to matching placebo and fol-
lowed for a median of 3.9 years. Results showed a significant
reduction in primary endpoints, total mortality (-9%,
P \ 0.05) and mortality and hospitalizations for CV disease
(-8%, P \ 0.01) in n-3 PUFAs group in comparison with
placebo, after adjustment for possible confounding factors
(previous HF hospitalization, pacemaker, aortic stenosis).
Although these results seem to be lower than expected, the
improvement of clinical outcomes was obtained in addition
to optimal medical therapy (including beta-blockers, ACE
inhibitors, AT1 and aldosterone antagonists) and correspond
to a NNT of 56 to prevent one death and NNT of 44 to prevent
an event (death or cardiovascular hospitalization).
In addition, more recently, the results of the echocar-
diographic substudy of GISSI-HF evidenced that chronic
administration of omega-3, in contrast to treatment with
rosuvastatin, was associated with a significant increase of
ejection fraction (EF) when compared to placebo (8.1 vs.
6.3% at 1 year, 11.1 vs. 8.2% at 2 years, 11.5 vs. 9.9% at
3 years, respectively; p = 0.005) [75]. These results
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suggest that the improved survival observed in HF patients
treated with omega-3 could be attributed to an improve-
ment of LV systolic function.
Despite this evidence, no study had specifically exam-
ined the effects of omega-3 on the ventricular function and
functional capacity in HF patients. To verify these effects,
we enrolled 133 patients with chronic HF due to non-
ischemic dilated cardiomyopathy, EF\45%, stable clinical
conditions on evidence-based medical treatment at maxi-
mum tolerated target doses for at least 6 months, into a
double-blind, placebo-controlled, two-arm study [76].
Participants were randomly allocated to active treatment
(1.0 g gelatin capsules containing 850–882 mg of eicosa-
pentaenoic (EPA) and docosahexaenoic (DHA) ethyl esters
in the average ratio EPA/DHA of 0.9:1.5) or to placebo
(1.0 g gelatin capsules containing olive oil). The treatment
dose was five capsules daily for the first month followed by
two capsules daily for the rest of the study. The primary
outcome was the change in LV systolic function expressed
as EF, while the secondary outcomes included: LV dia-
stolic function assessed by echocardiography; functional
capacity assessed by cardiopulmonary exercise testing
(CPET); and NYHA functional class. At the time of
enrollment and at 12-month follow-up patients underwent a
physical examination, ECG, blood draw for complete
blood count, comprehensive chemistry panel, inflammatory
cytokines, including TNF-a, IL-6 and IL-1, and serum free
fatty acids (FFAs) levels, echocardiographic study and
CPET. We found that at 12 months after randomization,
the n-3 PUFAs group and the placebo group differed sig-
nificantly (p \ 0.001) in regard to LV ejection fraction and
the other echocardiographic variables and in parameters of
functional capacity. In particular, the n-3 PUFA group
showed, at 1 year of follow-up compared with baseline, a
significant increase in EF (10.4 ± 9.5%, p \ 0.001) (Fig.
1), a significant reduction in diameter (EDD -1.8%,
p \ 0.0001; ESD -4.5%, p \ 0.001) and ventricular vol-
ume (EDV -2.5%, p \ 0.001; ESV -7.5% p \ 0.0001).
In contrast, in the placebo group at the end of the study
there was a significant reduction in EF as well as a statis-
tically significant increase in ventricular diameters and
volumes. In the group treated with n-3 PUFAs was also
observed an improvement of diastolic function was also
observed, expressed by a significant reduction of diastolic
dysfunction score (-4.74%, p = 0.004) compared with an
increase in this parameter in the placebo group (10.1%,
p \ 0.001). Positive results of treatment with omega-3
were observed for the functional capacity, expressed by an
increase of peak VO2 (6.2%, p \ 0.001) and duration of
exercise (7.7%, p \ 0.001) to cardiopulmonary stress test
and a reduction in NYHA functional class (from
1.88 ± 0.33 to 1.61 ± 0.49, p \ 0.001). In the placebo
group was shown at 12-month follow-up to a greater
degree of functional impairment was shown at a decline in
oxygen consumption and an increase in NYHA class.
During follow-up, the serum levels of inflammatory cyto-
kines (TNF-alpha, IL-6, IL-1) increased significantly in
the placebo group, while decreased in omega-3 group
(p \ 0.001). Of interest, throughout follow-up, lower hos-
pitalization rates for cardiovascular causes (15 vs. 39%,
respectively; p = 0.002) and for HF (6 vs. 30%, respec-
tively; p = 0.0002) were noted in the n-3 PUFAs-treated
patients compared to those on placebo (p \ 0.0002). The
results of our study suggest that n-3 PUFAs may act
favorably on ventricular function, both systolic and dia-
stolic, on left ventricular remodeling and functional
capacity, resulting in a lower incidence of HF and car-
diovascular hospitalizations.
Dose and optimal ratio of DHA/EPA
The potential favorable mechanisms of n-3 PUFAs in CV
diseases seem closely related to increased concentrations of
EPA and DHA in cell membranes [77]. The antiplatelet,
anti-inflammatory and lipid-lowering effects occur with
relatively high doses of EPA and DHA (3–4 g/day); on the
other hand the antiarrhythmic effect, the prevention of SCD
and the improvement in HF can be achieved with lower
doses (500–1,000 mg/day). The optimal dose and the ratio
of DHA and EPA has not been defined yet. DHA and EPA
are found in most kinds of fishes, particularly in fatty
fishes, usually in a 2:1 ratio, while pharmacological prep-
arations typically have a ratio of 2:3 or less [78]. Moreover,
while the administration of DHA can also increase levels of
EPA, the reverse process from EPA to DHA in humans
does not occur [79]. DHA is more represented than EPA in
myocyte membrane and its administration (alone or in
Fig. 1 Variations of the EF in the two study groups (from Nodari
[76])
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combination with EPA) seems to be more effective than
only EPA in preventing arrhythmias and SCD. Although
the beneficial effects on arrhythmias occurred at low doses,
the relative risk of SCD was inversely correlated with
baseline blood levels of n-3 PUFAs and protective effect in
patients at high risk of fatal arrhythmias, such as ICD
patients, was correlated with the concentration achieved
during treatment [64]. Similarly, an inverse correlation was
confirmed between tissue levels of DHA and CAD [80]. A
recent study [81] conducted in patients with HF showed an
association between DHA concentrations and degree of LV
remodeling: for diastolic diameter between 68 and 90 mm
(upper tertile) compared with diameters between 48 and
61 mm (lower tertile), as well as EF values between 9 and
25% (lower tertile) compared with values of EF from 35 to
50% (upper tertile), serum concentrations of DHA were
significantly lower (1 vs. 1.3%, p \ 0.001).
In our studies [77] we observed a significant inverse
association between baseline levels of omega-3 (particu-
larly DHA) and magnitude of LV remodeling and dys-
function, and between increased concentrations of DHA
and the improvement in these parameters at the end of
follow-up. These results suggest a prominent role of DHA
in the pathophysiology and then in the treatment of ven-
tricular dysfunction and remodeling.
As part of a therapy ‘‘tailored’’ for each patient, DHA
could be a new sensitive biomarker for monitoring and
diagnosis of systolic dysfunction and dilation in patients
with LV systolic HF, or could be used to determine the
optimal dosage and to monitor the response to therapy in
each patient.
Conclusion and future perspectives
In recent years there has been increasing evidence from
observational, experimental and clinical studies about the
beneficial effects of omega-3 in the prevention and treat-
ment of cardiovascular disease and their possible mecha-
nisms of action. However, sometimes conflicting results
have raised doubts and uncertainties. This is partly moti-
vated by the insufficient knowledge about the role of
omega-3 in complex biological mechanisms and cellular
system and by the publication of studies which seem
similar, but have significant differences in methodology
(case studies, dose, duration of follow-up, etc.) which can
lead to different results.
The GISSI-HF has not only provided important evidence
concerning the improvement of prognosis in patients with
HF treated with omega-3, but it also raised many questions
about the mechanisms underlying the favorable effect of n-3
PUFA in HF, in which patient could have more benefit from
the treatment with n-3 PUFA and which is the optimal dose.
In our experience, the n-3 PUFA supplementation in addi-
tion to an optimized medical therapy, was associated not
only with a reduction of arrhythmic risk, but also to an
improvement in EF and functional capacity, important
prognostic factors in HF patients.
Targeted studies are needed to respond to specific
questions, first the optimal dose to use and the optimal ratio
of EPA and DHA. The history of n-3 PUFAs in HF is
definitely still developing, but it is not too early to start
listening to its lessons. Among these, for example, there is
the importance of undertaking studies on the effects of
metabolic therapy in patients with advanced-stage of HF, in
which therapeutic intervention may help to recover dys-
functional, but vital, myocardium.
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